• Zhe He, Qian Dong, Yue Xi, and Rui Zheng.
• Shanxi Medical University, Taiyuan, Shanxi, China.
• Medicine (Baltimore). 2024 Jul 5; 103 (27): e38854e38854.

IntroductionEpidermolysis Bullosa Pruriginosa (EBP) is a persistent, recurring disease that seriously affects quality of life. Fewer than 100 cases of EBP have been reported to date. Numerous inflammatory dermatoses are driven by soluble inflammatory mediators, which rely on Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling, and inhibition of this pathway using Janus kinase (JAK) inhibitors might be a useful therapeutic strategy for these diseases.Patient ConcernsA male patient, 28 years of age, was admitted to our hospital because of recurrent papules, nodules, and intense itching on the trunk and extremities for 12 years. Repeated large and intense itching has seriously affected the patient normal life.DiagnosisThe patient was diagnosed with EBP based on examination results.InterventionsOral baricitinib tablets (2 mg, once a day) + Oral desloratadine citrate disodium tablets (8.8 mg, once a day) combined with topical compound flumethasone ointment and Fucidin cream.OutcomesThe patient skin rashes had subsided and flattened remarkable, and his itching was markedly relieved. The visual analogue scale (VAS) itching score of the patient gradually declined from 8 to 9 points to 2 to 3 points.ConclusionThis study confirms that baricitinib is effective and feasible in treating EBP, especially in remarkable relieving itching, which rendered new ideas for therapeutic approaches for EBP in the future.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

17 keywords...

hide…